Kenneth Cusi, MD, is a professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism at The University of Florida at Gainesville. He is also a faculty and researcher at the Endocrinology, Diabetes and Metabolism Division at the Veterans Administration Medical Center at Gainesville, FL.  

He received his medical degree and did his internal medicine residency in Buenos Aires, Argentina and completed a fellowship in Endocrinology, Diabetes and Metabolism at Baylor College of Medicine, Houston, Texas. He moved to San Antonio to work on the role of defects in insulin secretion and insulin resistance to the development of type 2 diabetes mellitus (T2DM), as well as on complications associated with T2DM, focusing on the underlying mechanisms of nonalcoholic fatty liver disease (NAFLD) in T2DM and its impact on dyslipidemia, diabetes control and cardiovascular disease.  

Dr. Cusi published the first randomized, controlled trial on the role of pioglitazone for the treatment of NASH for patients with prediabetes or T2DM (Belfort et al, NEJM 2006), followed by a recent long-term study confirming the value of pioglitazone in this population (Cusi et al, Annals Intern Med 2016). Current work centers on discovering the mechanism(s) leading to NASH and searching for novel treatments.

Dr. Cusi has published more than 150 original articles, reviews and book chapters in a broad spectrum of peer-reviewed journals.